Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity

ConditionsIntrathecal Dexmedetomidine Fentanyl Bupivacaine Spinal Anesthesia Above Knee Amputation Sarcomas Lower Extremity

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-60

SponsorNational Cancer Institute, Egypt

About this trial

The current work evaluated whether the combination of intrathecal dexmedetomidine and fentanyl provides superior postoperative analgesia to fentanyl alone when administered with hyperbaric bupivacaine.

Eligibility criteria

Qualifiers

Age from 18 to 60 years.

Both sexes.

American Society of Anesthesiologists (ASA) physical status of II-III.

Height between 150-185 cm.

Disqualifiers

Allergy to any of the investigated drugs.

History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel- blockers, or angiotensin-converting-enzyme inhibitors.

Contraindications to spinal anesthesia.

Pregnancy or lactation.

Trial design

Treatments tested in this trial

Fentanyl + Dexmedetomidine
Fentanyl

Treatment groups

58 Participants

are divided into 2 treatment groups

Sponsors and collaborators

National Cancer Institute, Egypt

Lead sponsor

Source ClinicalTrials.gov